SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRLS - Chrysalis : Any followers ? Any comments ?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (44)5/13/1998 1:48:00 PM
From: Mr Bond  Read Replies (1) of 51
 
CRLS is mainly into preclinical/Phase I, both of which are lower growth and lower margin businesses than Phase III, IBAH's main area of focus. Having said that, both companies have had difficulties making any money over the past few years in an industry where it's tough to lose money. That's why they make attractive turnaround acquisitions. CRLS looks cheap. It has the same backlog now (approx $16m) as it did a year ago, and last year the company generated $40m+ sales, but valuation is rock bottom. I can see MDS getting its check book out again, but for real this time. Anyone else out there with a view?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News